Market Overview

Global Oncology Biosimilars Market to 2026 - Robust Pipeline of Oncology Biosimilars Anticipated to Enter the Market by 2020


Global Oncology Biosimilars Market to 2026 - Robust Pipeline of Oncology Biosimilars Anticipated to Enter the Market by 2020

PR Newswire

DUBLIN, Aug. 31, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Global Oncology Biosimilars Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to's offering.

The global oncology biosimilars market was valued at US$ 1,651.5 Mn in 2017 expanding at a CAGR of 28.3% from 2018 to 2026.

The number of biosimilar approvals soared in the United States as five of nine approved biosimilars across different disease conditions received U.S. FDA approval. Furthermore, U.S. witnessed the approvals of oncology biosimilars such as Amgen's Mvasi (bevacizumab-awwb), a biosimilar to Genentech's Avastin for the treatment of lung, colorectal, kidney, brain and cervical cancers; and Mylan's Ogivri (trastuzumab-dkst), a biosimilar to Herceptin for treating breast cancer, gastric cancer, and gastrointestinal cancer.

In terms of drug class, the granulocyte colony-stimulating factor (G-CSF) held the largest share in the oncology biosimilars market owing to its early approvals in Europe and U.S. However, monoclonal antibodies class expected to grow at a highest growth rate and emerge as the largest market in 2026 due to recent approvals of Mvasi (bevacizumab-awwb) and Ogivri (trastuzumab-dkst) in the United States. Moreover, robust pipeline and patent expiration of major biologics during the forecast period would further assist the market growth of monoclonal antibodies. In terms of disease condition, neutropenia led the market due to approvals of filgrastim and Peg-filgrastim to multiple pharmaceutical companies in Europe and Asia Pacific. However, breast cancer is projected to proliferate at a humungous rate due to high prevalence of breast cancer globally and recent approval of trastuzumab in Europe and North America.

Europe dominated the global oncology biosimilars market in 2017 due to presence of approved oncology biosimilar such as filgrastim, trastuzumab and rituximab in the region. Moreover, the European Medicines Agency (EMA) have put forth guidelines for the approval of biosimilars through regulatory bodies such as European Society of Medical Oncology (ESMO).

North America is anticipated to exhibit rapid growth in oncology biosimilars market due to market entry of breakthrough oncology biosimilars and vigorous pipeline expected to hit the market during the forecast period.

The prominent players actively engaged in the oncology biosimilars market are Samsung Bioepis, Celltrion Inc., Biocon, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Sandoz Inc., Teva Pharmaceutical Industries Ltd., Apotex Inc., and BIOCAD.

Robust pipeline and ongoing clinical trials in U.S. and Europe are driving the oncology biosimilars market. For instance, Pfizer has six biosimilars in phase III of clinical trials, testing for drugs such as Rituxan/MabThera, Herceptin, Avastin and Humira

Key Market Movements:

  • Rising prevalence of cancer worldwide
  • Recent FDA approved biosimilars contributing towards the growth of oncology biosimilars market
  • Patent expirations of major biologics leading to inclination of generic pharmaceutical companies to venture in biosimilars
  • Partnerships and collaboration between biopharmaceutical companies to increase research and development of biosimilars
  • Robust pipeline of oncology biosimilars anticipated to enter the market by 2020 will also assist market growth

Key Topics Covered:

Chapter 1. Preface
1.1. Report Description
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Oncology Biosimilars Market Portraiture
2.2. Global Oncology Biosimilars Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Oncology Biosimilars Market, by Disease Condition, 2017 (US$ Mn)
2.4. Global Oncology Biosimilars Market Share, by Geography, 2017 (US$ Mn)

Chapter 3. Oncology Biosimilars: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Oncology Biosimilars Market, by Key Players, 2017

Chapter 4. Global Oncology Biosimilars Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Monoclonal Antibodies
4.3. Granulocyte Colony-Stimulating Factor (G-CSF)
4.4. Pipeline Analysis
4.4.1. Phase III Drug Analysis Rituximab Biosimilar Trastuzumab Biosimilar Filgrastim Biosimilar Bevacizumab Biosimilar
4.4.2. Tabular Representation of Phase I and Phase II Drugs

Chapter 5. Global Oncology Biosimilars Market, by Disease Condition, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Breast Cancer
5.3. Lung Cancer
5.4. Colorectal Cancer
5.5. Cervical Cancer
5.6. Blood Cancer
5.7. Neutropenia
5.8. Others (Brain Cancer, Stomach Cancer, etc.)

Chapter 6. Global Oncology Biosimilars Market, by Geography, 2016 - 2026 (US$ Mn)

Chapter 7. Company Profiles

  • Amgen, Inc.
  • Mylan N.V.
  • Samsung Bioepis Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Celltrion Healthcare
  • Novartis International AG
  • Biocon Limited
  • Biogen Idec
  • Sandoz
  • Dr. Reddy's Laboratory
  • Merck & Co.
  • Shanghai Henlius Biotech, Inc.
  • Biocad

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content with multimedia:

SOURCE Research and Markets

View Comments and Join the Discussion!